Award builds on company’s 23-year state partnership to accelerate better health outcomes for Medicaid membersMCLEAN, Va., Nov. 14, 2023 (GLOBE…
Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company working to accelerate…
BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage…
Amydis Novel Tracer Utilizes an Affordable, Accessible, Non-Invasive Approach as part of a Standard Office VisitSAN DIEGO, Nov. 14, 2023…
Phase 1 clinical study of GT-02287 initiated; dosing escalation on scheduleBETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics,…
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target…
SANTA CLARA, CA / ACCESSWIRE / November 13, 2023 / Zeto, Inc., an innovative EEG brain monitoring company, is excited…
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with…
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE…
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June,…